Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00332202
Registration number
NCT00332202
Ethics application status
Date submitted
30/05/2006
Date registered
1/06/2006
Date last updated
10/09/2018
Titles & IDs
Public title
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Query!
Scientific title
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Query!
Secondary ID [1]
0
0
H6Q-MC-JCBJ
Query!
Secondary ID [2]
0
0
9823
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non Hodgkin Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - enzastaurin
Treatment: Drugs - placebo
Experimental: A -
Placebo comparator: B -
Treatment: Drugs: enzastaurin
1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
Treatment: Drugs: placebo
oral, daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Disease-Free Survival
Query!
Assessment method [1]
0
0
Overall Disease-Free Survival (DFS) time is defined as the time from the date of study enrollment to the first date of objectively determined disease recurrence (progressive disease) or death from any cause. DFS was assessed according to International Working Group recommendations. Progressive disease (PD) is defined as a = 50% increase from the lowest point in the sum of the product of the diameters (SPD) of any previously identified abnormal node for partial or nonresponders, or the appearance of any new lesion during or at the end of therapy.
Query!
Timepoint [1]
0
0
Baseline to Measured Progressive Disease or Death from Any Cause (up to 80.30 months)
Query!
Secondary outcome [1]
0
0
Disease Free Survival at 2 Years
Query!
Assessment method [1]
0
0
Disease-free survival at 2 years (DFS2) is defined as the rate of DFS at 2 years from the date of study enrollment and is determined using the distribution of overall DFS times. Disease-free survival rates at 2 years will be estimated using the Kaplan-Meier method.
Query!
Timepoint [1]
0
0
Baseline to 2 Years
Query!
Secondary outcome [2]
0
0
Event-Free Survival
Query!
Assessment method [2]
0
0
Overall Event-Free Survival (EFS) time is defined as the time from the date of study enrollment to the first date of objectively determined disease recurrence (progressive disease), institution of a new anti-cancer treatment, or death from any cause. Progressive disease (PD) is defined as a = 50% increase from the lowest point in the sum of the product of the diameters (SPD) of any previously identified abnormal node for partial or nonresponders, or the appearance of any new lesion during or at the end of therapy.
Query!
Timepoint [2]
0
0
Baseline to Objective PD, Start of New Therapy or Death From Any Cause (up to 76.81 months)
Query!
Secondary outcome [3]
0
0
Event-Free Survival at 2 Years
Query!
Assessment method [3]
0
0
Event-Free Survival at 2 years (EFS2) is defined as the rate of EFS at 2 years from the date of study enrollment and is determined using the distribution of overall EFS times. Event-free survival rates at 2 years will be estimated using the Kaplan-Meier method.
Query!
Timepoint [3]
0
0
Baseline to 2 Years
Query!
Secondary outcome [4]
0
0
Overall Survival
Query!
Assessment method [4]
0
0
Overall survival (OS) time is defined as the time from the date of study enrollment to the date of death from any cause.
Query!
Timepoint [4]
0
0
Baseline to Date of Death from Any Cause (up to 80.30 months)
Query!
Secondary outcome [5]
0
0
Number of Participants With Treatment-Emergent Adverse Events
Query!
Assessment method [5]
0
0
Number of participants with treatment-emergent adverse events.
Query!
Timepoint [5]
0
0
First dose through 30 days post-study treatment discontinuation (up to 81.30 months)
Query!
Secondary outcome [6]
0
0
Quality of Life: Change From Baseline in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Score
Query!
Assessment method [6]
0
0
The FACT-Lym assesses health-related quality of life (HRQoL) in participants with non-Hodgkin lymphoma. It includes the 27-item cancer-specific FACT-G (General), which assesses physical, social/family, emotional and functional well-being, plus a 15-item subscale that assesses concerns specific to lymphoma. Each item is scored on a scale from 0 (not at all) to 4 (very much), yielding a possible score of 0-168, with higher scores representing better HRQoL. This analysis utilized mixed-effect model repeated measure (MMRM) analysis of change from baseline adjusting for baseline covariates.
Query!
Timepoint [6]
0
0
Baseline, Month 2; Baseline, Month 4; Baseline, Month 6; Baseline, Month 12; Baseline, Month 18; Baseline, Month 24; Baseline, Month 36
Query!
Secondary outcome [7]
0
0
Change From Baseline in EuroQol-5D (EQ-5D) Score
Query!
Assessment method [7]
0
0
The EQ-5D instrument is a participant-rated questionnaire used to evaluate health status. The EQ-5D assesses five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression) that participants rate using three levels (no problem, some problem, or extreme problem), as well as overall health status. The five dimensions can be combined using country-specific weights to create an estimate of overall health status score. The possible values for score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. This analysis utilized mixed-effect model repeated measure (MMRM) analysis of change from baseline in the EQ-5D for the United Kingdom population-based index score adjusting for baseline covariates.
Query!
Timepoint [7]
0
0
Baseline, Month 6; Baseline, Month 24; Baseline, Month 33
Query!
Secondary outcome [8]
0
0
Translational Research: DFS Participants With Diffuse Large B-cell Lymphoma (DLBCL) Germinal-center B-cells (GCB) Versus Non-germinal-center B-cells
Query!
Assessment method [8]
0
0
Reported are the DFS for GCB and non-GCB status. DLBCL molecular subtypes of GCB/non-GCB using Hans' algorithm were determined by protein expression by immunohistochemistry (IHC) staining was used to assess molecular subtype characterization of GCB and non-GCB.
Query!
Timepoint [8]
0
0
Baseline to 24 months (2 years)
Query!
Secondary outcome [9]
0
0
Translational Research: DFS of Participants With Diffuse Large B-cell Lymphoma (DLBCL) Protein Kinase C-ß2 (PKC-ß2) Expression
Query!
Assessment method [9]
0
0
Reported are the DFS based on PKC-ß2 protein expression. Immunohistochemistry (IHC) staining was performed to assess protein expression of PKC-ß2 in cytoplasm scored for percent of tumor cells stained, and using 50% positive staining as the cutoff for high/low expression (high expression: \>=50% staining, low expression: \<50% staining).
Query!
Timepoint [9]
0
0
Baseline to 94.5 months
Query!
Secondary outcome [10]
0
0
Pharmacokinetics: Average Steady-State Concentration (Cavg,ss) for Total Analyte
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Month 2, Month 4: Predose
Query!
Eligibility
Key inclusion criteria
* Clinical diagnosis of diffuse large B cell lymphoma
* Recently completed R-CHOP therapy and achieved remission
* International Prognostic Index (IPI) score 3,4,5
* At least 18 years of age
* Agree to study follow-up schedule
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Have received therapy other than R-CHOP for lymphoma
* Serious medical condition such as infection,second cancer,heart disease
* Received radiation to more than one lesion
* Unable to swallow tablets
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
758
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Garran
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Gosford
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Casuarina
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Woolloongabba
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Heidelberg
Query!
Recruitment hospital [6]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Prahran
Query!
Recruitment hospital [7]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [3]
0
0
0811 - Casuarina
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [6]
0
0
3181 - Prahran
Query!
Recruitment postcode(s) [7]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alaska
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oklahoma
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Utah
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Wisconsin
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Brugge
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Brussels
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Gent
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Leuven
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Roeselare
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Belo Horizonte
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Campinas
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Goiania
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Rio De Janeiro
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
São Paulo
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Alberta
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
British Columbia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Ontario
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Quebec
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Saskatchewan
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Beijing
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Chengdu
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Guang Zhou
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Hangzhou
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Nanjing
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Shanghai
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Suzhou
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Brno
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Olomouc
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Prague
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
Herlev
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Odense
Query!
Country [46]
0
0
Finland
Query!
State/province [46]
0
0
Helsinki
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Avignon
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Bayonne
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
La Roche Sur Yon
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Le Mans
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Nantes
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Nice
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Nimes
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Pessac
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Rennes
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Vandoeuvre Les Nancy
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Berlin
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Chemnitz
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Erlangen
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Frankfurt
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Giessen
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Hamburg
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Homburg
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Kassel
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Mainz
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Muenchen
Query!
Country [67]
0
0
Greece
Query!
State/province [67]
0
0
Athens
Query!
Country [68]
0
0
Greece
Query!
State/province [68]
0
0
Haidari/Athens
Query!
Country [69]
0
0
Greece
Query!
State/province [69]
0
0
Thessaloniki
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Budapest
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Miskolc
Query!
Country [72]
0
0
India
Query!
State/province [72]
0
0
Mumbai
Query!
Country [73]
0
0
India
Query!
State/province [73]
0
0
New Delhi
Query!
Country [74]
0
0
India
Query!
State/province [74]
0
0
Pune
Query!
Country [75]
0
0
India
Query!
State/province [75]
0
0
Secunderabad
Query!
Country [76]
0
0
India
Query!
State/province [76]
0
0
Trivandrum
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Aviano
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Bergamo
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Bologna
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Milano
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Pisa
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Reggio Emilia
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Rome
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Vicenza
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Aichi
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Fukuoka
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Gunma
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Kanagawa
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Kyoto
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Mie
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Miyagi
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Nagasaki
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Okayama
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Shiga
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Tokyo
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Daegu
Query!
Country [97]
0
0
Korea, Republic of
Query!
State/province [97]
0
0
Goyang-Si
Query!
Country [98]
0
0
Korea, Republic of
Query!
State/province [98]
0
0
Hwasun-Gun
Query!
Country [99]
0
0
Korea, Republic of
Query!
State/province [99]
0
0
Seoul
Query!
Country [100]
0
0
Mexico
Query!
State/province [100]
0
0
Col. Florida
Query!
Country [101]
0
0
Mexico
Query!
State/province [101]
0
0
Guadalajara
Query!
Country [102]
0
0
Mexico
Query!
State/province [102]
0
0
Mexico City
Query!
Country [103]
0
0
Mexico
Query!
State/province [103]
0
0
Monterrey
Query!
Country [104]
0
0
Mexico
Query!
State/province [104]
0
0
San Luis Potosi
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Toluca
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Lublin
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Olsztyn
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Poznan
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Warsaw
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Wroclaw
Query!
Country [111]
0
0
Portugal
Query!
State/province [111]
0
0
Coimbra
Query!
Country [112]
0
0
Portugal
Query!
State/province [112]
0
0
Lisbon
Query!
Country [113]
0
0
Portugal
Query!
State/province [113]
0
0
Santa Maria Da Feira
Query!
Country [114]
0
0
Puerto Rico
Query!
State/province [114]
0
0
San Juan
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Hospitalet Llobregat
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Madrid
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Oviedo
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Salamanca
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Santander
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Toledo
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Valencia
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Zaragoza
Query!
Country [123]
0
0
Sweden
Query!
State/province [123]
0
0
Lund
Query!
Country [124]
0
0
Sweden
Query!
State/province [124]
0
0
Umea
Query!
Country [125]
0
0
Sweden
Query!
State/province [125]
0
0
Uppsala
Query!
Country [126]
0
0
Taiwan
Query!
State/province [126]
0
0
Changhua
Query!
Country [127]
0
0
Taiwan
Query!
State/province [127]
0
0
Chiayi City
Query!
Country [128]
0
0
Taiwan
Query!
State/province [128]
0
0
Kaohsiung
Query!
Country [129]
0
0
Taiwan
Query!
State/province [129]
0
0
Liouying/Tainan
Query!
Country [130]
0
0
Taiwan
Query!
State/province [130]
0
0
Neihu Taipei
Query!
Country [131]
0
0
Taiwan
Query!
State/province [131]
0
0
Taichung
Query!
Country [132]
0
0
Taiwan
Query!
State/province [132]
0
0
Tainan
Query!
Country [133]
0
0
Taiwan
Query!
State/province [133]
0
0
Taipei
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Devon
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
East Sussex
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Kent
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Scotland
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00332202
Query!
Trial related presentations / publications
Crump M, Leppa S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2016 Jul 20;34(21):2484-92. doi: 10.1200/JCO.2015.65.7171. Epub 2016 May 23.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00332202
Download to PDF